CureVac (NASDAQ:CVAC) Shares Gap Down – Should You Sell?

CureVac (NASDAQ:CVAC)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $2.88, but opened at $2.80. CureVac shares last traded at $2.81, with a volume of 83,628 shares.

Analyst Ratings Changes

Separately, JMP Securities reiterated a “market outperform” rating and set a $16.00 price objective on shares of CureVac in a research note on Monday, September 16th.

CureVac Stock Performance

The stock’s fifty day simple moving average is $2.93 and its 200-day simple moving average is $3.26. The company has a market capitalization of $633.58 million, a price-to-earnings ratio of 5.18, a price-to-earnings-growth ratio of 2.04 and a beta of 2.61. The company has a current ratio of 2.29, a quick ratio of 2.28 and a debt-to-equity ratio of 0.09.

CureVac (NASDAQ:CVAC) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). The firm had revenue of $15.55 million during the quarter, compared to analysts’ expectations of $10.07 million. CureVac had a net margin of 20.72% and a return on equity of 25.55%. Analysts predict that CureVac will post 0.05 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. boosted its stake in CureVac by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company’s stock worth $127,000 after buying an additional 16,792 shares during the last quarter. Ballentine Partners LLC increased its stake in CureVac by 58.6% during the third quarter. Ballentine Partners LLC now owns 22,755 shares of the company’s stock worth $67,000 after acquiring an additional 8,406 shares during the last quarter. International Assets Investment Management LLC purchased a new position in shares of CureVac in the 3rd quarter worth about $35,000. Private Advisor Group LLC acquired a new stake in shares of CureVac in the third quarter worth $30,000. Finally, Signaturefd LLC boosted its stake in shares of CureVac by 26.9% during the 3rd quarter. Signaturefd LLC now owns 27,970 shares of the company’s stock valued at $82,000 after buying an additional 5,927 shares during the last quarter. 17.26% of the stock is currently owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.